Understanding how STING signaling is controlled in the body
Factors regulating strength and duration of STING signaling
['FUNDING_R01'] · BROAD INSTITUTE, INC. · NIH-10897959
This study is looking at how a part of our immune system called the cGAS-STING pathway works, especially when it goes into overdrive and causes long-lasting inflammation, which can lead to conditions like Aicardi Goutières Syndrome, to help find better ways to manage or treat these issues.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BROAD INSTITUTE, INC. (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-10897959 on ClinicalTrials.gov |
What this research studies
This research investigates the cGAS-STING pathway, which plays a crucial role in the immune response by detecting DNA from pathogens and cancer cells. The study aims to identify the genes that regulate the activity, movement, and breakdown of STING, particularly in conditions where its signaling becomes excessive, leading to chronic inflammation. Using advanced techniques like CRISPR knockout screens, the researchers will explore how disruptions in these regulatory processes can contribute to diseases such as Aicardi Goutières Syndrome. Patients may benefit from insights gained into how to better manage or treat conditions associated with abnormal STING signaling.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with autoimmune diseases, particularly those related to STING pathway dysregulation, such as Aicardi Goutières Syndrome.
Not a fit: Patients without autoimmune conditions or those not affected by STING signaling abnormalities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for autoimmune diseases and chronic inflammatory conditions linked to STING signaling.
How similar studies have performed: Other research has shown promising results in understanding the cGAS-STING pathway, indicating that this approach has potential for significant advancements in treatment.
Where this research is happening
CAMBRIDGE, UNITED STATES
- BROAD INSTITUTE, INC. — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HACOHEN, NIR — BROAD INSTITUTE, INC.
- Study coordinator: HACOHEN, NIR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Aicardi Goutieres syndrome